Registered title, quoted from ClinicalTrials.gov
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05528055, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
Inclusion criterion 1
Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
Exclusion criterion 2
Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
Exclusion criterion 3
ECOG Performance Status 0 or 1.
Inclusion criterion 4
History of a second malignancy within 2 years (as defined in the protocol).
Exclusion criterion 5
Gestating or Lactating women.
Exclusion criterion 13
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05528055, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
- Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available.
- At least one evaluable or measurable lesion (as defined in the protocol).
- ECOG Performance Status 0 or 1.
- Life expectancy ≥12 weeks.
- Adequate organ function (as defined in the protocol).
- Reproductive criteria (as defined in the protocol).
Exclusion Criteria:
- Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption.
- Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
- Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
- Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
- History of a second malignancy within 2 years (as defined in the protocol).
- Active uncontrolled or symptomatic lung disease (as defined in the protocol).
- Intracranial hypertension or active uncontrolled or symptomatic CNS metastases.
- Known or suspected hypersensitivity to study medications.
- Known active uncontrolled or symptomatic CNS metastases.
- The investigator determined that the patient should not participate in the study.
- Known mental illness or substance abuse that may disrupt therapy.
- Clinically significant cardiac abnormalities (as defined in the protocol).
- Gestating or Lactating women.
- Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
- The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.
Quoted from ClinicalTrials.gov, NCT05528055, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05528055, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.